ABOUT US
A biotechnological company which mission is to generate robust clinical therapeutic and diagnostic candidates available for development and commercialization partnerships with pharmaceutical companies.
R&D
Digna develops new drugs from CIMA, a leading private biomedical research centre, focused on four clinical areas: oncology, cardiovascular physiopathology, neuroscience, and gene therapy and hepatology.
PRODUCTS
DIGNA biotech has 18 products including 12 therapeutic candidates, 4 clinical-Stage Products, panning 23 indications across 6 key franchises, as well as 4 diagnostic tests, and 2 research products.
PARTNERING
DIGNA leverages world-class scientific and clinical expertise to push medical innovations through early clinical development, reduce financial risk, and thereby increase their partnering appeal to suitable drug and diagnostic developers.
NEWS
|
02-01-2012 Topical formulation of peptide 144 transforming growth factor (TGF) beta 1 inhibitor |
|
14-11-2011 Digna Biotech regains all rights to Disitertide (P144) to treat skin conditions |
Events
Newsletter
Would you like to receive updates about Digna Biotech? Sign up for our newsletter.
© Digna Biotech · Legal information · Company associated to ASEBIO
